Purpose: Our aim was to determine the eff ect of metformin exposure on survival in patients with advanced pancreatic adenocarcinoma (PAC). Methods: A retrospective cohort study was conducted using Th e Health Improvement Network (THIN), a primary care electronic medical record database from the United Kingdom (2003)(2004)(2005)(2006)(2007)(2008)(2009)(2010). Th e study cohort included all subjects with a diagnostic code for incident PAC and a pre-existing diagnosis of type 2 diabetes mellitus (T2DM). Subjects were classifi ed as exposed if they were prescribed metformin around the time of PAC diagnosis (between 6 months prior and 1 month aft er). A secondary analysis was performed only on exposed subjects without prior (i.e., 6 months before PAC diagnosis) exposure to metformin. Th e primary outcome was overall survival. Th e analysis was performed using univariate and multivariable Cox proportional-hazards models. Results: Th e study included 516 subjects with pre-existing T2DM and PAC, 247 of which were exposed to metformin. In univariate and multivariable analysis, there was no diff erence in survival between those exposed and those unexposed to metformin in the primary analysis (HR=1.11 [0.89, 1.38], p=0.367) or the secondary analysis focusing on new starters of metformin (HR=1.09 [0.80, 1.47], p=0.585). Conclusion: Metformin use is not associated with an improvement in survival in subjects with advanced PAC.
Purpose: To perform a retrospective exploratory post-hoc subgroup analysis to assess the effi cacy and safety of CREON ® in patients with exocrine pancreatic insuffi ciency (EPI) and medical history of diabetes mellitus (DM). Methods: Th is was an analysis of S245.3.124 (NCT00414908), a phase-III, multicenter, double-blind, randomized, placebo-controlled parallel-group trial. Patients with confi rmed EPI due to chronic pancreatitis (CP) or pancreatic surgery (PS) were randomized to receive pancrelipase (PL) delayed-release (CREON®), 12,000 lipase units capsules (72,000 lipase units per meal, 36,000 per snack) or placebo. Fift y-two patients completed the 1-week double-blind period (24 PL, 28 placebo). DM was present in 34/52 (65.4%) participants (16 PL, 18 placebo) . Th e primary endpoint was the change in coeffi cient of fat absorption (CFA) from baseline to end of randomized period. Secondary endpoints included safety parameters. Data was analyzed using non-parametric analysis of covariance. Results: Th e mean change in CFA from baseline was signifi cantly greater in the PL+ DM group compared to placebo + DM (35.2 ± 18.6 vs. 6.92 ± 12.5, p<.0001) . No signifi cant diff erence was observed in the number of subjects with at least one treatment-emergent adverse event (TEAE) in the PL+ DM group compared to placebo + DM (29.4% vs. 26.3%). Th e effi cacy and safety results in the PL+ no DM group (n=8) compared to placebo + no DM (n=10) were consistent with the fi ndings for the two DM groups: change in CFA from baseline (24.2 ± 17.8 vs. 11.8 ± 12.4, p=.0046) , number of subjects with at least one TEAE (0.0% vs. 10.0%). Th e effi cacy and safety results in the PL+ DM group were also consistent with the overall trial results (change in CFA from baseline 32.1 ± 18.5% vs. 8.8 ± 12.5%, p<0.0001, number of subjects with at least one TEAE (20.0% vs. 20.7%). Conclusion: PL (CREON®) was eff ective in treating fat maldigestion with a TEAE rate similar to that of placebo in patients with EPI due to CP or PS with or without medical history of DM. Disclosure: Dr. Whitcomb has served as a consultant to Abbott; Dr. Bodhani, Dr. Fuldeore, Dr. Sander-Struckmeier, Dr. Beckmann and Dr. Pollack Purpose: Human equilibrative nucleoside transporter 1 (hENT1) is the primary membrane channel through which gemcitabine (GEM) enters pancreatic tumor cells. Patients (pts) whose resected pancreatic ductal adenocarcinoma (PDAC) express low levels of hENT1 may derive little benefi t from GEM therapy. Recently, a validated diagnostic immunohistochemistry (IHC) test has been developed. Here, we prospectively test this diagnostic in a series of 204 retrospectively collected formalin-fi xed paraffi n-embedded (FFPE) PDAC tissues. Methods: Based on demographic and disease characteristics, this cohort is representative of typical adjuvant and metastatic PDAC patients. One hundred thirty four primary and 70 metastatic PDAC pre-treatment specimens were dichotomized into high versus low hENT1 tumor expression by an independent pathologist blinded to treatment and outcome. Results: Overall, 39% of primary and 23% of metastatic cases had high levels of tumor hENT1. In the primary tumor set 90/134 pts went on to receive GEM-based therapy; pts with high hENT1 tumor levels had a median overall survival (OS) of 35 months compared to 15 months in those with low levels of tumor hENT1 (HR=0.48). In 44 non-GEM treated pts there was no association between hENT1 tumor expression and overall survival (median OS of 26 versus 28 months in pts with hENT1 high and low, respectively; HR=0.8).
In 63/70 metastatic specimens from patients treated with GEM the median OS was 25 versus 10 months (HR=0.64) for high versus low hENT1 tumors respectively.
Conclusion:
In conclusion, we have prospectively tested the utility of the hENT1 IHC diagnostic in predicting clinical outcome in an institutional series of FFPE tumors from PDAC pts. Th e assay was eff ective in identifying GEM-treated pts with a poorer OS outcome using both primary and metastatic FFPE tumor tissues. Th is diagnostic is being prospectively tested in a global pivotal clinical trial of CO-101 (CP-4126), a lipid drug conjugate of GEM designed to enter tumor cells independently of hENT1, versus GEM in metastatic PDAC ("LEAP", NCT01124786 Purpose: Recurrent acute pancreatitis (AP) is oft en considered to have a benign course; however, this has not been clearly demonstrated in the studies. Th e aim was to compare the clinical course of those with an initial episode of AP to those with recurrent AP stratifi ed by the number of prior episodes. Methods: Th is retrospective cohort study included consecutive AP patients admitted to the Cleveland Clinic between 2007 and 2012. AP was defi ned according to ACG guidelines based on the presence of two of the following: 1) typical abdominal pain, 2) serum amylase and/or lipase ≥3 times the upper limit of normal, and 3) characteristic fi ndings of AP on CT scan. Rates of severe AP, ICU admission, new local complications, elevated BUN and BISAP score, SIRS, and mortality were compared. Results: Th ree hundred thirty four patients were included; 220 (66%) were admitted for their fi rst AP episode. On univariable analysis, those with fi rst episode were more likely to have severe AP, be admitted to the ICU, and have elevated BUN levels and BISAP scores (Table) . On multivariable analysis, the fi rst episode of AP was an independent predictor of severe AP and ICU admission. For each prior episode of AP, the odds of having severe AP decreased by 57%. Also noted was a signifi cantly higher proportion of chronic pancreatitis in those with recurrent attacks (5% for fi rst attack, 18% for second, 20% for third, 44% for >3, p<0.001).
Patients presenting with recurrent AP may be at decreased risk of a clinically severe course. 
